A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs (ENABLE-2)
A Phase 3, Multicenter, Open-Label, Randomized Study of ELVN-001 Versus Investigator-Selected Tyrosine Kinase Inhibitor (TKI) of Dasatinib, Nilotinib, or Bosutinib, in Adult Participants With Chronic Myeloid Leukemia in Chronic Phase (CP-CML), Previously Treated With One or More TKIs
The study is designed to compare the efficacy of ELVN-001 versus Investigator-selected tyrosine kinase inhibitor (TKI) for adults with previously treated chronic myeloid leukemia in the chronic phase (CP-CML). The Investigator-selected TKI will be one of the following standard of care therapies: Dasatinib, Nilotinib, or Bosutinib.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This is a multicenter, open-label, randomized study of ELVN-001 versus Investigator-selected TKI (Dasatinib, Nilotinib, or Bosutinib) in adult participants with CP-CML previously treated with one or more TKIs. Participants will be randomized to receive either ELVN-001 or their investigator's choice of one of the comparator TKIs (Dasatinib, Nilotinib, or Bosutinib). Treatment will continue until one of the protocol defined treatment discontinuation criteria are met. Participants will then enter a long-term follow-up period for survivorship and updates on disease status.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Enliven Medical Information
- Número de teléfono: +1 6505475814
- Correo electrónico: MedInfo@enliventherapeutics.com
Ubicaciones de estudio
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Reclutamiento
- Winship Cancer Institute
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46260
- Reclutamiento
- Investigative Clinical Research of Indiana, LLC
-
-
New Jersey
-
Morristown, New Jersey, Estados Unidos, 07960
- Reclutamiento
- Atlantic Health System
-
-
Utah
-
Ogden, Utah, Estados Unidos, 84405
- Reclutamiento
- Community Center Trials of Utah
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female at least 18 years of age
- Diagnosis of chronic myeloid leukemia in chronic phase (CP-CML)
- Prior treatment with 1 or more BCR::ABL1 TKI(s)
- Failure or intolerance on the immediate prior TKI
- Adequate end organ function as measured by blood tests
Exclusion Criteria:
- Known T315I mutation
- Known second chronic phase of CML after previous progression to accelerated or blast phase
- Any serious or uncontrolled medical disorder
- QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec
- Previous treatment with a hematopoietic stem-cell transplantation
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: ELVN-001
ELVN-001 |
ELVN-001 orally daily |
|
Comparador activo: Investigator-selected TKI
Randomized to receive one of the following investigator's choice TKIs: Dasatinib, Nilotinib, or Bosutinib |
TKI orally daily
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Major Molecular Response (MMR) Rate at Week 24 - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: 24 weeks
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale. |
24 weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Major Molecular Response (MMR) Rate at Week 96 - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: 96 weeks
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale. |
96 weeks
|
|
Change in overall scores, individual scales, and health status based on participant reporting - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years
|
Validated questionnaires will be used to assess disease-related symptoms, functioning, and tolerability. |
planned total follow-up duration of 5 years
|
|
Major Molecular Response (MMR) at all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale |
planned total follow-up duration of 5 years
|
|
Major Molecular Response (MMR) by all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale |
planned total follow-up duration of 5 years
|
|
Time to Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years
|
The time to MMR is defined as the time from the date of randomization to the date of the first documented occurrence of MMR |
planned total follow-up duration of 5 years
|
|
Duration of Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years
|
Duration of MMR is defined as the time between the date of the first achievement of MMR and the earliest date of loss of MMR or CML-related death |
planned total follow-up duration of 5 years
|
|
BCR::ABL1 ratio ≤ 1% at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years
|
BCR::ABL1 transcript levels are measured by quantitative polymerase chain reaction (qPCR). The ratio is calculated for BCR::ABL/ABL1 based on the International Scale |
planned total follow-up duration of 5 years
|
|
Time to treatment failure - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years
|
Time to treatment failure is defined as the time from randomization to the first date of any of the following events: treatment failure as defined per protocol |
planned total follow-up duration of 5 years
|
|
Progression-free survival - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years
|
Progression-free survival is defined as the time from randomization to the earliest occurrence of progression or death from any cause |
planned total follow-up duration of 5 years
|
|
Overall survival (OS) - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years
|
OS is defined as the time from randomization to death from any cause |
planned total follow-up duration of 5 years
|
|
MR4 and MR4.5 at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MR4 is defined as a ratio BCR::ABL/ABL1 ≤ 0.01% on the International Scale and MR4.5 is defined as a ratio BCR::ABL/ABL1 ≤ 0.0032% on the International Scale |
planned total follow-up duration of 5 years
|
|
Time to treatment discontinuation due to adverse event (AE) - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years
|
This is defined as the time from randomization to discontinuation of study treatment due to an adverse event |
planned total follow-up duration of 5 years
|
|
Characterization of adverse events (AE) and clinically relevant findings, including laboratory abnormalities, electrocardiogram (ECG) changes, and other safety data - ELVN-001 versus Investigator-selected TKI
Periodo de tiempo: planned total follow-up duration of 5 years
|
Characteristics of AEs will be evaluated to assess safety and tolerability profiles |
planned total follow-up duration of 5 years
|
|
Plasma concentrations of ELVN-001 in participants treated with ELVN-001 will be assessed at all scheduled collection timepoints
Periodo de tiempo: planned total follow-up duration of 5 years
|
Relevant pharmacokinetic parameters will be evaluated |
planned total follow-up duration of 5 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Neoplasias
- Enfermedad crónica
- Atributos de la enfermedad
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Leucemia Mieloide
- Enfermedades de la médula ósea
- Leucemia
- Trastornos mieloproliferativos
- Translocación Genética
- Aberraciones cromosómicas
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades hemic y linfáticas
- Leucemia, Mielógena, Crónica, BCR-ABL Positivo
- Cromosoma filadelfia
- Leucemia mieloide en fase crónica
- Compuestos de azufre
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Tiazoles
- Azoles
- Pirimidinas
- Dasatinib
- nilotinib
- bosutinib
Otros números de identificación del estudio
Otros números de identificación del estudio
- ELVN-001-301
- 2026-526266-25-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .